Some therapeutic sectors saw their compound annual growth rate drop 10% or more, deviating from long-term trends. Sales should return to normal growth trajectories as backlogs in procedures continue to clear out.
As the Biden administration leans into the Cancer Moonshot 2.0, the life sciences industry has the opportunity to launch a new era of precision oncology. How can we accelerate progress toward truly personalized medicine and revolutionize cancer care?
Overheard at the J.P. Morgan Healthcare Conference
Executives detailed plans to take on more risk, build on advances in life sciences, and expressed optimism in Medicare Advantage, despite missing enrollment targets.
And How Stakeholders Can, Literally, Save the World
Climate change will be the biggest impact on global health. The healthcare industry may not respond in time.
In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.
Whoever's closest to the consumer will be the gatekeeper of the industry.
A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.
Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.
Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.
How pharmaceutical companies can better define, measure, and deliver value to patients.